Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 7/2016

01-07-2016 | Original Article

Circulating serum levels of angiopoietin-1 and angiopoietin-2 in nasopharynx and larynx carcinoma patients

Authors: Murat Emin Güveli, Derya Duranyildiz, Ahmet Karadeniz, Elif Bilgin, Murat Serilmez, Hilal Oguz Soydinc, Vildan Yasasever

Published in: Tumor Biology | Issue 7/2016

Login to get access

Abstract

We aimed to determine the serum levels of angiogenic factors, namely angiopoietins, in nasopharyngeal and laryngeal carcinoma patients. We also aimed to seek the relation of these molecules with tumor grade and their utility as diagnostic biomarkers. We evaluated angiopoietin 1 and 2 levels innasopharynx and larynx cancer patients before treatment. Angiopoietin 2 levels were significantly elevated in larynx carcinoma patients and tended to be elevated in nasopharynx cancer patients compared with healthy controls. However, angiopoietin 1 levels were similar in cancer patients and controls. Angiopoietin 1 levels were significantly higher in nasopharyngeal cancer patients with advanced stages compared to earlier stages. On the other hand, angiopoietin 2 levels were similar in advanced and earlier stage cancer patients.
Literature
1.
Carla C, Daris F, Cecilia B, Francesca B, Francesca C, Paolo F. Angiogenesis in head and neck cancer: a review of the literature. J Oncol. 2012;2012:358472.CrossRefPubMed
2.
Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma. Med Oncol. 2008;25:431–6.CrossRefPubMed
3.
Demasi AP, Silva CA, Silva AD, Furuse C, Soares AB, Altemani A, et al. Expression of the vascular endothelial growth factor and angiopoietins in mucoepidermoid carcinoma of salivary gland. Head Neck Pathol. 2012;6:10–5.CrossRefPubMed
4.
Melen-Mucha G, Niedziela A, Mucha S, Motylewska E, Lawnicka H, Komorowski J, et al. Elevated peripheral blood plasma concentrations of tie-2 and angiopoietin 2 in patients with neuroendocrine tumors. Int J Mol Sci. 2012;13:1444–60.CrossRefPubMedPubMedCentral
5.
Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer. 2010;10:575–85.CrossRefPubMed
6.
Bessa V, Loukides S, Hillas G, Delimpoura V, Simoes D, Kontogianni K, et al. Levels of angiopoietins 1 and 2 in induced sputum supernatant in patients with COPD. Cytokine. 2012;58:455–60.CrossRefPubMed
7.
Gardizi M, Kurschat C, Riese A, Hahn M, Krieg T, Mauch C, et al. A decreased ratio between serum levels of the antagonistic angiopoietins 1 and 2 indicates tumour progression of malignant melanoma. Arch Dermatol Res. 2012;304:397–400.CrossRefPubMed
8.
Karatzanis AD, Koudounarakis E, Papadakis I, Velegrakis G. Molecular pathways of lymphangiogenesis and lymph node metastasis in head and neck cancer. Eur Arch Otorhinolaryngol. 2012;269:731–7.CrossRefPubMed
9.
Volkova E, Willis JA, Wells JE, Robinson BA, Dachs GU, Currie MJ. Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer. Br J Cancer. 2011;104:51–9.CrossRefPubMed
10.
Wieloch M, Swiatkowska M, Libiszewski M, Hedayati M, Drozda R, Kolomecki K. Assessment of the selected, late phase of angiogenesis factors’ concentration in colorectal cancer patients. Pol Merkur Lekarski. 2009;27:466–9.PubMed
11.
Sallinen H, Heikura T, Laidinen S, Kosma VM, Heinonen S, Yla-Herttuala S, et al. Preoperative angiopoietin-2 serum levels: a marker of malignant potential in ovarian neoplasms and poor prognosis in epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20:1498–505.PubMed
12.
Yuan HT, Khankin EV, Karumanchi SA, Parikh SM. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol. 2009;29:2011–22.CrossRefPubMedPubMedCentral
13.
14.
Ribatti D, Vacca A, Presta M. The discovery of angiogenic factors: a historical review. Gen Pharmacol. 2000;35:227–31.CrossRefPubMed
15.
Chien CY, Su CY, Chuang HC, Fang FM, Huang HY, Chen CM, et al. Angiopoietin-1 and -2 expression in recurrent squamous cell carcinoma of the oral cavity. J Surg Oncol. 2008;97:273–7.CrossRefPubMed
16.
Mitsutake N, Namba H, Takahara K, Ishigaki K, Ishigaki J, Ayabe H, et al. Tie-2 and angiopoietin-1 expression in human thyroid tumors. Thyroid. 2002;12:95–9.CrossRefPubMed
17.
Nagata J, Kijima H, Hatanaka H, Tokunaga T, Kamochi J, Abe Y, et al. Angiopoietin-1 and vascular endothelial growth factor expression in human esophageal cancer. Int J Mol Med. 2002;10:423–6.PubMed
18.
Xu G, Lou W, Sun Z, Zhang P. Expression of angiopoietin-1, 2 and its relationship with angiogenesis in laryngeal squamous cell carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2008;22:772–6.PubMed
19.
Li C, Feng HC, Chen JC, Song YF. Expression and significance of angiopoietin-1 and angiopoietin-2 in oral squamous cell carcinoma. Ai Zheng. 2005;24:1388–93.PubMed
20.
Li C, Zhang B, Wang ZH, Chen JC, Li B, Wang SX, et al. Significance of a reversal expression of the angiopoietin-1 and 2 in oral squamous cell carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009;44:412–8.PubMed
Metadata
Title
Circulating serum levels of angiopoietin-1 and angiopoietin-2 in nasopharynx and larynx carcinoma patients
Authors
Murat Emin Güveli
Derya Duranyildiz
Ahmet Karadeniz
Elif Bilgin
Murat Serilmez
Hilal Oguz Soydinc
Vildan Yasasever
Publication date
01-07-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 7/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4777-0

Other articles of this Issue 7/2016

Tumor Biology 7/2016 Go to the issue

Original Article

MicroRNAs modulating angiogenesis: miR-129-1 and miR-133 act as angio-miR in HUVECs

Original Article

Doxorubicin nanobubble for combining ultrasonography and targeted chemotherapy of rabbit with VX2 liver tumor

Original Article

Expression and mechanisms of long non-coding RNA genes MEG3 and ANRIL in gallbladder cancer

Original Article

Predictable factors for lymph node metastasis in early gastric cancer analysis of clinicopathologic factors and biological markers

Original Article

Overexpression of long non-coding RNA LOC400891 promotes tumor progression and poor prognosis in prostate cancer

Original Article

Evaluation of RIP1K and RIP3K expressions in the malignant and benign breast tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits